Phase Ib/II Study of QL1706 + Fruquintinib + SCRT vs. Standard Third-Line Therapy in Unresectable Liver-Metastatic pMMR/MSS Colorectal Cancer: Safety, Tolerability, and Efficacy.
Clinical trial NCT07353268 · NOT_YET_RECRUITING
Trial details
- NCT number
- NCT07353268
- Sponsor
- Tao Zhang
- Status
- NOT_YET_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2026-01-21
- Primary completion
- 2027-08-31
- Enrollment
- 76
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.